TG Therapeutics' Initial Data From Its Phase 1 Trial Of Azercabtagene Zapreleucel In Patients With Progressive Multiple Sclerosis Demonstrates 89% Of Evaluable Participants Had Stable Or Improved Disability Scores At Day 90

Loading news article.

TG Therapeutics' Initial Data From Its Phase 1 Trial Of Azercabtagene Zapreleucel In Patients With Progressive Multiple Sclerosis Demonstrates 89% Of Evaluable Participants Had Stable Or Improved Disability Scores At Day 90 | WAPE

TG Therapeutics' Initial Data From Its Phase 1 Trial Of Azercabtagene Zapreleucel In Patients With Progressive Multiple Sclerosis Demonstrates 89% Of Evaluable Participants Had Stable Or Improved Disability Scores At Day 90

Article summary

Related companies

Comments —